Cambridge, MA-based OpenEvidence, which offers an AI chatbot to help physicians, raised $75M from Sequoia at a $1B valuation, its first outside funding round
AI startup OpenEvidence is raising a fresh round of capital from Sequoia to scale its chatbot for doctors.
Context & Ripple Effects
This first institutional round gave OpenEvidence a well-capitalized backer as it sought to expand a physician-focused AI product. Later coverage shows that early financing became the base for much larger rounds, including a $200M financing at a $6B valuation in October 2025.
The company’s trajectory matters because it connects clinician-facing AI adoption with repeat venture financing: its subsequent $250M round at a $12B valuation suggests investors treated the product category as capable of supporting unusually large private-company valuations.
First-order effects
- OpenEvidence gains $75M to scale its chatbot for physicians, while Sequoia becomes its first outside institutional investor at a $1B valuation.
- The funding gives the company more capacity to build and distribute its medical AI product before later, larger financing rounds.
Second-order effects
- The deal raises the competitive funding bar for other companies selling AI tools to clinicians: prospective rivals must show credible physician utility and distribution to attract comparable backing.
- Sequoia’s investment helps concentrate investor attention on physician-facing AI products, potentially making capital and recruiting more competitive within the category.
Third-order effects
- If repeat funding and adoption continue to reinforce one another, clinician AI could develop into a market led by a smaller number of highly financed platforms rather than many lightly funded point solutions.
- The later description of OpenEvidence as ad-supported indicates that business-model choices—not just model quality—may increasingly determine whether clinical AI products can sustain broad access.
The trend: This is an early example of venture capital concentrating around AI products that target a defined professional workflow and can demonstrate a path from specialized use to large-scale distribution.